Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

Johnson & Johnson Stock: Analyst Estimates & Ratings

Johnson & Johnson has outpaced the broader market and the healthcare sector in 2025, and analysts remain optimistic about the stock’s prospects.

Barchart

Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report

The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted access.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks That Aren't Sweating the Coming 200% Drug Tariffs

On July 8, US President Donald Trump shook the biopharmaceutical sector by announcing a tariff of up to 200% on pharmaceuticals, which would take effect “very soon.” 80% of prescription drugs sold in the US are made abroad, a statistic the President wants to flip on its head.

Benzinga

2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025

These blue-chip stocks offer a rare combination of stability, resilience, and moderate growth.

Barchart

4 Major Stocks Raise 2025 Guidance, Analyst Targets Rise

With solid Q2 results and 2025 guidance increases, Wall Street is upgrading these four stocks. Analysts now see palpable upside in one streaming stalwart.

MarketBeat

10 Brand Names That Are Actually Owned By the Same Company

Ever feel like you’re making diverse choices at the grocery store or pharmacy? In reality, many of the brands you think are competitors are actually owned by the same parent company. These corporate giants dominate entire industries, using multiple brand identities to give the illusion of variety. Once you understand…

Grocery Coupon Guide

Read news from The Economist, FT, and more,
with one subscription

Stock Of The Day: Breakout In Johnson & Johnson

Johnson Johnson (NYSE:JNJ) stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance. As you can see on the chart below, that's the case here. This level was also resistance in March.

Benzinga

Want Steady Income? 3 Top Dividend Stocks for July 2025

Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility

MarketBeat

Johnson & Johnson Ups Forecast, Beats On EPS—But Wall Street Is Cautious

Shares of Johnson Johnson (NYSE:JNJ) are under pressure Thursday, despite a strong second-quarter earnings report.

Benzinga

Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings

Johnson Johnson (NYSE:JNJ) posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.

Benzinga

Rigetti Computing, Netflix, Johnson & Johnson, United Airlines And ASML: Why These 5 Stocks Are On Investors' Radars Today

U.S. stocks moved higher today, with the Dow Jones gaining more than 200 points, or 0.5%, to close at 44,254.78. The Nasdaq added 0.25% to finish at 20,730.49, while the SP 500 advanced 0.3% to 6,263.70.

Benzinga

JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now

Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.

MarketBeat

Johnson & Johnson Raises FY25 Forecast, Joins Rigetti Computing, Unity Software, Brighthouse Financial And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were slightly lower, with the Dow Jones index falling around 0.1% on Wednesday.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Johnson & Johnson Lifts Annual Forecast After Strong Cancer Drugs, Medtech Performance

Johnson Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, beating the consensus of $2.68.

The Independent UK

Asian shares mostly decline as worries continue over Trump's tariffs

Asian shares are trading mostly lower as worries about President Donald Trump’s latest updates to his tariffs weighed on investor sentiments

MarketBeat

These 3 Undervalued Stocks Could Surge as Value Rotation Nears

A rotation back into value stocks may be imminent in today's market, giving investors a chance to expose themselves into a catch up play.

Grocery Coupon Guide

7 Shampoo Brands Facing Consumer Lawsuits

Hair care should make you look better, not worse. Yet several major shampoo brands are now facing serious legal challenges from consumers who claim these products caused hair loss, scalp irritation, and other injuries. These lawsuits highlight growing concerns about potentially harmful ingredients in everyday hair care products.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Johnson & Johnson Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Johnson Johnson (NYSE:JNJ) will release earnings results for the second quarter, before the opening bell on Wednesday, July 16.

Barchart

Here's What to Expect From Johnson & Johnson's Next Earnings Report

Johnson & Johnson is set to unveil its Q2 results in the upcoming month, and analysts expect its profitability to observe a notable decline.

The Guardian - UK

Les Squires obituary

Other lives: Non-woven fabrics designer who created new materials for use in industry and agriculture

MarketBeat

3 Top Dividend Stocks Analysts Are Bullish on Right Now

With earnings season coming to an end, investors are looking for new catalysts; here are three blue-chip companies with strong analyst support

Barchart

Johnson & Johnson Stock: Is JNJ Outperforming the Healthcare Sector?

Johnson & Johnson has outpaced the broader healthcare sector over the past year, and analysts remain optimistic about the stock’s prospects.

Barchart

Build a Bulletproof Dividend Portfolio With These 5 Defensive Stocks

These defensive stocks pay reliable dividends.

The Independent UK

New documentary explores the Tylenol cyanide murders - and the reason tamper-proof seals are on everything

In 1982, seven people in Chicago died after taking Tylenol laced with lethal cyanide, causing fear and a change in consumer product safety. Two suspects emerged but there were no arrests or answers. Now, a new Netflix docuseries, out May 26, examines the decades-old mystery offering an exclusive interview with…

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.